Biofrontera vs Ocular Therapeutix
BFRI and OCUL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BFRI and OCUL compare
Ocular Therapeutix is the larger company, worth 131 times as much as Biofrontera ($1.4B against $10.4M).
Biofrontera grew revenue faster over the last twelve months (29.8% versus −9.7% for Ocular Therapeutix).
Biofrontera keeps more of each dollar of sales as profit, with a net margin of −12.7% compared with −649% at Ocular Therapeutix.
Biofrontera scores higher on the StockData Score (9 against 3 for Ocular Therapeutix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BFRI | OCUL |
|---|---|---|
| Size and price | ||
| Market cap | $10.4M | $1.4B |
| Share price | $0.700 | $6.21 |
| Change, 1 year | −28.1% | −46.0% |
| Change, 5 years | −98.7% | −7.2% |
| Beta (5Y) | 0.97 | 1.25 |
| Employees | 92 | 325 |
| StockData Score | ||
| Total score | 9 (better) | 3 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 4 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.2× (better) | 27.1× |
| P/B | – | 3.1× |
| FCF yield | −53.4% | −19.6% (better) |
| Fair value | – | $4.70 |
| Margin of safety | – | −32.2% |
| Growth | ||
| Revenue growth (TTM) | 29.8% (better) | −9.7% |
| Revenue growth, 5Y average | 17.2% | 24.4% (better) |
| Profitability | ||
| Gross margin | – | 87.3% |
| Operating margin | −14.1% (better) | −681% |
| Net margin | −12.7% (better) | −649% |
| FCF margin | −11.5% (better) | −530% |
| Return on equity | – | −93.5% |
| Financial health | ||
| Debt / equity | – | 0.17 |
| Interest coverage | – | −30.6× |
| Current ratio | 0.78 | 9.12 (better) |
| Altman Z-score | −7.80 | 0.92 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 18.6% | 94.4% |
| Held by insiders | 23.6% | 2.9% |
| Insider net buying, 12 months | – | −$2.5M |
| Short interest, % of float | 1.7% | 13.6% |
Go deeper
- BFRI stock overview
- BFRI income statement
- BFRI valuation and score
- OCUL stock overview
- OCUL income statement
- OCUL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.